Episodes
Friday Apr 14, 2023
Friday Apr 14, 2023
You’ve probably encountered many patients who have experienced muscle symptoms after starting a statin. Statin-associated muscle symptoms (SAMS) contribute to treatment discontinuation and significantly increase cardiovascular (CV) adverse events and mortality. What strategies do you recommend to increase statin tolerance?
Guest Author: Rick Hess, PharmD, CDCES, BCACP
Music by Good Talk
Tuesday Jul 26, 2022
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Tuesday Jul 26, 2022
Tuesday Jul 26, 2022
Physical activity is critical to preventing and treating diabetes and reduces cardiovascular disease (CVD) and mortality. Although moderate-to-high intensity aerobic exercise of any type is likely beneficial, cycling is particularly attractive because it is a low-impact exercise (e.g. easier on the joints) and can potentially be used as a transportation method.
Guest Author: Kristin Lutek, PharmD, BCACP, CDCES
Special Guest: Seena L. Haines, PharmD, BCACP, NBC-HWC
Music by Good Talk
Friday Jul 08, 2022
Annual Wellness Visits: Pharmacists Closing Care Gaps
Friday Jul 08, 2022
Friday Jul 08, 2022
Many older adults do not receive recommended screening exams or treatments and frequently take multiple medications that place them at high risk of adverse effects and drug-drug interactions. Pharmacists performing an Annual Wellness Visit (AWV) provides an opportunity to conduct a comprehensive medication review to identify and correct medication-related problems as well as close care gaps.
Guest Authors: Brenna Gelen, PharmD and Nicole Slater, PharmD, BCACP
Music by Good Talk
Friday Mar 11, 2022
Friday Mar 11, 2022
Traditionally, hypertension management involves a stepwise approach where agents are titrated and added. Thus, achieving optimal BP control requires close follow-up, time, and resources. Outside of these logistics, providers are prone to clinical inertia (aka fail to advance therapy when they should) and sometimes “push back” from patients who experience the burdens of treatment and follow-up. Perhaps it’s time to reconsider our approach to managing hypertension.
Guest Authors: Erin Connolly, PharmD and Laura Varnum, PharmD, BCACP
Music by Good Talk
Friday Apr 26, 2019
Need a VITALity Boost? Rethink Vitamin D and Fish Oil Supplements
Friday Apr 26, 2019
Friday Apr 26, 2019
Vitamin D and fish oil (aka omega-3 fatty acids) were the most widely used vitamin and nutritional supplement in 2011-2012. Both have been commonly touted for their potential benefits in reducing cancer and cardiovascular disease. While vitamin D and omega-3 fatty acid supplements are wildly popular, the evidence supporting their health benefits is inconclusive and inconsistent. The VITAL study sought to determine whether vitamin D and/or marine omega-3 fatty acids can prevent cardiovascular disease (CVD) and cancer when used by the general population.
Guest Authors: Anthony M Todd, PharmD; Sean E Smithgall, PharmD, BCACP; and Nicole A Slater, PharmD, BCACP
Music by Good Talk
Wednesday Jan 09, 2019
Top Ten Things Every Clinician Should Know About the 2018 Cholesterol Guidelines
Wednesday Jan 09, 2019
Wednesday Jan 09, 2019
The American Heart Association / American College of Cardiology (AHA/ACC) Task Force recently published the 2018 Guideline on the Management of Blood Cholesterol. The guidelines writing committee had representation from 12 organizations, including the National Lipid Association, American Diabetes Association, and the American Pharmacists Association — all of whom endorsed the guidelines. The previous guidelines (published in 2013) were intended to answer some specific clinical questions and significantly changed our approach to treatment. The 2018 guidelines provide a more comprehensive set of recommendations, akin to the (older) National Heart, Lung, and Blood Institute Adult Treatment Panel (ATP) III guidelines last published in 2002!
Guest Authors: Dawn Fuke, Pharm.D., BCPS, and Zach Conroy, PharmD, BCACP
Music by Good Talk
Friday Dec 14, 2018
Another Attempt to ARRIVE at an Answer Using Aspirin for Primary Prevention
Friday Dec 14, 2018
Friday Dec 14, 2018
Daily low-dose aspirin has long been considered a “wonder drug” for its cardioprotective effects, particularly in patients with pre-existing cardiovascular and cerebrovascular disease; however, despite decades of research, the use of aspirin to prevent a first event is less certain. In 2014, the Food and Drug Administration (FDA) responded to a citizen petition requesting the labeled indications for low dose aspirin be updated to include primary prevention. The FDA concluded that the evidence “fail[ed] to establish that aspirin reduces the risk of primary myocardial infarction (MI) in patients with a coronary heart disease (CHD) risk of 10% or more for over 10 years.” The Asprin to Reduce Risk of Initial Vascular Events (ARRIVE) study is intended to address this gap in our knowledge.
Guest Authors: Amy St. Amand, PharmD, BCPS and Christine Borowy, PharmD, BCPS
Music by Good Talk
Friday Dec 07, 2018
Does a “One-Size-Fits-All” Aspirin Dosing Approach Still Hold WEIGHT?
Friday Dec 07, 2018
Friday Dec 07, 2018
Personalized medicine is at the forefront of health care today, focusing on how best to tailor the treatment approach to each person. But should we be thinking about personalizing the approach for prevention as well? The one-dose-fits-all approach has been used in nearly all aspirin studies. What is poorly understood is the influence of body weight. Perhaps the reason why aspirin has resulted in only modest benefits in clinical trials might be related to under (and over) dosing based on patient weight.
Podcast Case: Weight-based Dosing of Aspirin
Guest Author: Marina Maes, PharmD, BCPS
Music by Good Talk
Friday Nov 23, 2018
Friday Nov 23, 2018
Aspirin is no doubt beneficial in patients with overt vascular disease for the secondary prevention of myocardial infarction, stroke, or cardiovascular death. However, evidence supporting use of aspirin for primary prevention in patients who have not had a cardiovascular event is far less compelling. The clinical uncertainty of aspirin use for the primary prevention of CV events in patients with diabetes is reflected in the different recommendations in current guidelines. The investigators of the ASCEND (A Study of Cardiovascular Events in Diabetes) trial set out to determine the safety and efficacy of daily aspirin use in patients with diabetes without known occlusive arterial disease.
Podcast Case: ASA Use in DM - Evidence ASCENDing?
Guest Author: Kirstie Perry, Pharm.D.
Music by Good Talk
Friday Dec 15, 2017
Friday Dec 15, 2017
We interview Eric MacLaughlin, Joseph Saseen, and Kristin Rieser about the ACC/AHA Guidelines for the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in Adults released in November 2017. Dr. MacLaughin, a member of the Guideline Writing Committee, gives a insiders view of the guidelines development process and explains the rationale for lower blood pressure goals. Drs. Saseen and Rieser talk about some of the practical considerations that we all must consider as we move forward to making these recommendations a reality.
Guests: Kristin Rieser, Pharm.D., Joseph Saseen, Pharm.D, and Eric MacLaughlin, Pharm.D.
Music by Good Talk